Cleared Traditional

K912839 - LAPAROOPTX(TM) INTRAOPER DEFLECT CHOLEDOCHOSCOPE (FDA 510(k) Clearance)

Class I Gastroenterology & Urology device.

K912839 · Baxter Healthcare Corp · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1991
Decision
91d
Days
Class 1
Risk

K912839 is an FDA 510(k) clearance for the LAPAROOPTX(TM) INTRAOPER DEFLECT CHOLEDOCHOSCOPE. Classified as Filiform And Filiform Follower (product code FBW), Class I - General Controls.

Submitted by Baxter Healthcare Corp (Irvine, US). The FDA issued a Cleared decision on September 25, 1991 after a review of 91 days - within the typical 510(k) review window.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.5520 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Gastroenterology & Urology review framework, consistent with the majority of Class II 510(k) submissions.

View all Baxter Healthcare Corp devices

Submission Details

510(k) Number K912839 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 26, 1991
Decision Date September 25, 1991
Days to Decision 91 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
39d faster than avg
Panel avg: 130d · This submission: 91d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FBW Filiform And Filiform Follower
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 876.5520
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.